Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | HRH2 | P25021 | 1/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | DRD3 | P35462 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009409 | 1.00 | SLC6A4 (0.75) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL2006721 | 1.00 | SLC6A4 (0.75) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL7688733 | 0.99 | SLC6A4 (0.73) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL30681653 | 0.90 | SLC6A4 (0.69) | SLC6A4 | |
| SCHEMBL1120 | 0.90 | SLC6A4 (0.75) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL143594 | 0.88 | SLC6A4 (0.73) | SLC6A4 | |
| SCHEMBL141623 | 0.88 | SLC6A4 (0.83) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL29582298 | 0.85 | SLC6A4 (0.56) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL2872832 | 0.85 | SLC6A4 (0.68) | SLC6A4 | |
| SCHEMBL3408141 | 0.85 | SLC6A4 (0.57) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251410-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | SUN PHARMA GLOBAL FZE (AE) | 2011-10-13 | — | — | US | claimed |
| US-7989645-B2 | Escitalopram with chiral purity greater than 99.8% obtained in more than 50% yield; without chiral chromatographic separation | SUN PHARMA GLOBAL FZE (AE) | 2011-08-02 | — | — | US | claimed |
| US-7964742-B2 | including preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile intermediate by cyclization of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)benzonitrile in the presence of a base | SUN PHARMA GLOBAL FZE (AE) | 2011-06-21 | — | — | US | claimed |
| US-20100249437-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | SUN PHARMA GLOBAL FZE (AE) | 2010-09-30 | — | — | US | claimed |
| EP-2141156-A1 | Process for Preparation of Citalopram and Enantiomers | Sun Pharma Global FZE (AE) | 2010-01-06 | — | — | EP | claimed |
| US-20090326249-A1 | Process for Preparation of Citalopram and Enantiomers | SUN PHARMA GLOBAL FZE (AE) | 2009-12-31 | — | — | US | claimed |
| US-20080177096-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2008-07-24 | — | — | US | claimed |
| EP-1797060-A2 | \"PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS\ | Sun Pharmaceutical Industries Limited (IN) | 2007-06-20 | — | — | EP | claimed |
| US-7148364-B2 | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile | SUN PHARMACEUTICAL INDUSTRIES (IN) | 2006-12-12 | — | — | US | claimed |
| US-7019153-B2 | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-03-28 | — | — | US | claimed |
| WO-2006021971-A2 | 'PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS' | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-03-02 | — | — | WO | claimed |
| EP-1486492-A9 | A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran. | Sun Pharmaceutical Industries Limited (IN) | 2005-06-08 | — | — | EP | claimed |
| US-20050043550-A1 | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-02-24 | — | — | US | claimed |
| US-20050004380-A1 | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido]-3-substituted-3-cephem-4-carboxylic acid | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-01-06 | — | — | US | claimed |
| EP-1486492-A2 | A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran. | Sun Pharmaceuticals Industries Ltd. (IN) | 2004-12-15 | — | — | EP | claimed |
| WO-2003057132-A2 | PROCESS FOR THE PREPARATION OF 1-[3-(DIMETHYLAMINO)PROPYL]-1-(4-FLUOROPHENYL)- 1,3-DIHYDRO-5-ISOBENZOFURAN CARBONITRILE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-07-17 | — | — | WO | claimed |
| WO-1996001107-A1 | USE OF PHARMACEUTICAL AGENTS FOR RESTORING, ALLEVIATION, OR TREATMENT OF IMMUNODEFICIENCY, INCLUDING THE ALLEVIATION OR TREATMENT OF THE IMMUNE DYSFUNCTION RELATED TO INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUSES (HIV) OR RELATED VIRUSES | HOFMANN BO ARNE (DK) | 1996-01-18 | — | — | WO | claimed |
| WO-2020060011-A1 | NOVEL PREPARATION METHOD FOR CITALOPRAM AND ESCITALOPRAM USING CARBONATES | (주)유케이케미팜 | 2020-03-26 | — | — | WO | disclosed |
| WO-2000013648-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000011926-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004380-A1 | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido]-3-substituted-3-cephem-4-carboxylic acid | P4HA1, HYOU1, HDHD5 | SLC6A4 3581/4885NPC1 1346/4885SLC22A1 2737/4885 |
| US-20110251410-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | HTR1F, CYP2F1, CYP4F11 | SLC6A4 142/4885NPC1 901/4885SLC22A1 1861/4885 |
| US-20090326249-A1 | Process for Preparation of Citalopram and Enantiomers | HTR1F, CYP2F1, CYP4F11 | SLC6A4 71/4885NPC1 1448/4885SLC22A1 1550/4885 |
| US-20100249437-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | HTR1F, CYP2F1, CYP4F11 | SLC6A4 71/4885NPC1 1448/4885SLC22A1 1550/4885 |
| US-20050043550-A1 | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile | LMNA, LMNB1, LMNB2 | SLC6A4 3525/4885NPC1 93/4885SLC22A1 3309/4885 |
| US-20080177096-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | HTR1F, CYP2F1, CYP4F11 | SLC6A4 142/4885NPC1 901/4885SLC22A1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.